Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.\u00a0It was approved for medical use in the United States and in the European Union in 2015.<\/p>\n
If PRAXBIND (idarucizumab) Injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
Note:<\/strong><\/em> NEWS \/ UPDATES<\/strong><\/p>\n Praxbind is a medicine used\u00a0to neutralise the effects of dabigatran\u00a0(the active substance of Pradaxa), a medicine that treats and prevents blood clots. Praxbind is used to rapidly stop the anticlotting effect of dabigatran, before emergency surgery or in case of life-threatening bleeding.<\/p>\n Source Details: Patient Information<\/a><\/p>\n IPN, New Delhi can facilitate patient to import of “PRAXBIND (idarucizumab) Injection”<\/strong> in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please\u00a0email IPN healthcare Support Team <\/a>for PRAXBIND (idarucizumab) Injection price list or cost in India. on Mr. Tarun:- +91 9891 296 838 \/ Mr. Neeraj:- +91 9811 747 774.<\/strong><\/em><\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/em><\/p>\n\n
PRAXBIND (idarucizumab) injection, for intravenous use Initial U.S. Approval: 2015<\/h2>\n
\n\n
\n Brand Name:<\/strong><\/td>\n PRAXBIND<\/td>\n<\/tr>\n \n Generic Name:<\/strong><\/td>\n idarucizumab<\/td>\n<\/tr>\n \n Strength:<\/strong><\/td>\n Injection: 2.5 g\/50 mL solution in a single-use vial<\/td>\n<\/tr>\n \n Manufacturer:<\/strong><\/td>\n Boehringer Ingelheim Pharmaceuticals, Inc<\/td>\n<\/tr>\n \n Approved By:<\/strong><\/td>\n EMA, USFDA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n